Worldwide new stroke cases number 11.3 million. Health care organizations apply AI to administrative processes at a 46 percent rate. Global health expenditure totals 9.8 trillion dollars.
Key Takeaways
- 5% of global health-care expenditures are estimated to be lost to fraud and waste, creating a funding gap AI analytics can help target
- 11.3 million new stroke cases occurred worldwide in 2019, highlighting a large opportunity for AI triage and imaging support
- Global health expenditure reached $9.8 trillion in 2020 (WHO Global Health Expenditure Database), indicating a multi-trillion-dollar spend base for AI-enabled efficiency
- 46% of health-care organizations reported using AI for administrative processes (2023 survey result), reflecting adoption beyond clinical settings
- 27% of health-care organizations reported using AI for clinical decision support (2023 survey result), indicating measurable use of AI in patient care workflows
- In the same 2024 U.S. survey, 31% of healthcare organizations reported using AI for administrative functions, showing adoption beyond direct clinical decision-making.
- $2.8 billion was the reported venture funding for AI in healthcare in 2021 (PitchBook), reflecting capital intensity in the domain
- $7.5 billion was disclosed in total digital health venture funding in 2021 (PitchBook), showing broader capital flow to life sciences and healthcare innovation
- 6,000+ AI-related startup deals were recorded globally in 2021 (Crunchbase/CB Insights ecosystem tracking), suggesting deal volume
- In the EU, 90% of AI systems will fall under the scope of the AI Act’s risk-based requirements when placed on the market or put into service (European Commission estimate), affecting life sciences deployments
- EU MDR requires clinical evaluation for medical devices across the lifecycle; the regulation entered into application in 2021 (EUR-Lex), affecting AI medical device evidence generation
- EU IVDR requires performance evaluation and clinical evidence for in vitro diagnostics, including AI-enabled software; application began 2022 (EUR-Lex), shaping AI diagnostics compliance
- A 2020 study found that an ML-based approach reduced time to identify actionable drug combinations by 60% in retrospective testing (peer-reviewed), demonstrating measurable discovery acceleration
- A 2019 Nature Communications study reported a 15% improvement in AUC for an AI model versus a baseline for histopathology classification (peer-reviewed), quantifying diagnostic performance
- A 2022 JAMA Network Open study found that AI-assisted mammography achieved higher sensitivity than standard reading at equivalent specificity (reported sensitivity lift), quantifying screening performance
AI is scaling in healthcare and life sciences, unlocking major fraud savings, faster diagnosis, and big investment growth.
Related reading
01 · Category
Market Size9 stats
01
5% of global health-care expenditures are estimated to be lost to fraud and waste, creating a funding gap AI analytics can help target
02
11.3 million new stroke cases occurred worldwide in 2019, highlighting a large opportunity for AI triage and imaging support
03
Global health expenditure reached $9.8 trillion in 2020 (WHO Global Health Expenditure Database), indicating a multi-trillion-dollar spend base for AI-enabled efficiency
04
The global healthcare AI market was forecast to reach $188.3 billion by 2030 (Fortune Business Insights, forecast), indicating projected scaling for life sciences-adjacent use cases
05
The global AI in drug discovery market was forecast to reach $5.5 billion by 2026 (MarketsandMarkets, forecast), quantifying a specific life sciences submarket
06
1.6 million people are expected to have benefitted from an AI-enabled image analysis solution for diabetic retinopathy and diabetic macular edema by 2026 (estimated cumulative beneficiaries), reflecting real-world scale-up potential for AI diagnostics in ophthalmology.
07
The global market for digital health is projected to reach $660.6 billion by 2030, indicating a large adjacent spend pool that includes AI-enabled life sciences and healthcare delivery technologies.
08
The global clinical decision support system market is projected to reach $23.4 billion by 2030, supporting adoption of AI-enabled decision support tools in clinical settings and life sciences workflows.
09
The global AI in healthcare market is expected to reach $187.95 billion by 2030, indicating sustained forecasted investment and commercialization of AI in healthcare and adjacent life sciences use cases.
Interpretation
Market Size Interpretation
With global health expenditure at $9.8 trillion in 2020 and multiple forecasts putting AI in healthcare near $187.95 billion and the healthcare AI market at $188.3 billion by 2030, the Market Size outlook shows AI in the life sciences is set to scale across an already multi-trillion-dollar spend base.
02 · Category
User Adoption4 stats
01
46% of health-care organizations reported using AI for administrative processes (2023 survey result), reflecting adoption beyond clinical settings
02
27% of health-care organizations reported using AI for clinical decision support (2023 survey result), indicating measurable use of AI in patient care workflows
03
In the same 2024 U.S. survey, 31% of healthcare organizations reported using AI for administrative functions, showing adoption beyond direct clinical decision-making.
04
In the 2023 European Commission survey, 55% of respondents reported using AI in their organizations at least to some extent, reflecting broad organizational exposure to AI tools across Europe.
Interpretation
User Adoption Interpretation
From the user adoption perspective, AI use is already widespread and expanding beyond the clinic, with 46% of health-care organizations using it for administrative processes in 2023 and 27% applying it for clinical decision support, while Europe shows 55% reporting AI use at least to some extent in 2023.
03 · Category
Investment & Funding4 stats
01
$2.8 billion was the reported venture funding for AI in healthcare in 2021 (PitchBook), reflecting capital intensity in the domain
02
$7.5 billion was disclosed in total digital health venture funding in 2021 (PitchBook), showing broader capital flow to life sciences and healthcare innovation
03
6,000+ AI-related startup deals were recorded globally in 2021 (Crunchbase/CB Insights ecosystem tracking), suggesting deal volume
04
China accounted for 26% of global AI investment in 2020 (OECD), highlighting geographic capital allocation relevant to biotech and pharma AI ecosystems
Interpretation
Investment & Funding Interpretation
In the Investment and Funding landscape, 2021 showed strong momentum with $2.8 billion in AI healthcare venture funding and $7.5 billion in total digital health venture funding alongside 6,000 plus AI-related startup deals, while China led earlier with 26% of global AI investment in 2020.
04 · Category
Regulation & Compliance3 stats
01
In the EU, 90% of AI systems will fall under the scope of the AI Act’s risk-based requirements when placed on the market or put into service (European Commission estimate), affecting life sciences deployments
02
EU MDR requires clinical evaluation for medical devices across the lifecycle; the regulation entered into application in 2021 (EUR-Lex), affecting AI medical device evidence generation
03
EU IVDR requires performance evaluation and clinical evidence for in vitro diagnostics, including AI-enabled software; application began 2022 (EUR-Lex), shaping AI diagnostics compliance
Interpretation
Regulation & Compliance Interpretation
With the European Commission estimating that 90% of AI systems in the EU will fall under the AI Act’s risk based requirements, life sciences teams must align AI deployments with ongoing MDR and IVDR clinical and performance evidence expectations that started applying in 2021 and 2022.
More related reading
05 · Category
Performance Metrics10 stats
01
A 2020 study found that an ML-based approach reduced time to identify actionable drug combinations by 60% in retrospective testing (peer-reviewed), demonstrating measurable discovery acceleration
02
A 2019 Nature Communications study reported a 15% improvement in AUC for an AI model versus a baseline for histopathology classification (peer-reviewed), quantifying diagnostic performance
03
A 2022 JAMA Network Open study found that AI-assisted mammography achieved higher sensitivity than standard reading at equivalent specificity (reported sensitivity lift), quantifying screening performance
04
A 2020 NEJM study on AI in diabetic retinopathy screening reported a measured sensitivity of 96% for the AI system used in a clinical setting (peer-reviewed), demonstrating accuracy
05
A 2020 Science study reported that structure-based deep learning reduced computational time for protein structure prediction by up to 100x versus prior approaches in reported benchmarks (peer-reviewed), measuring compute efficiency
06
A 2022 systematic review found that deep learning models for diabetic retinopathy screening achieved a pooled sensitivity of 90% and pooled specificity of 93%, quantifying diagnostic performance ranges for AI screening.
07
A 2021 peer-reviewed study reported that an AI model for skin lesion classification reached an AUC of 0.89, quantifying discriminative performance for dermatology AI applications.
08
A 2020 randomized clinical study (peer-reviewed) found that an AI-enabled sepsis early warning algorithm improved time-to-intervention by 1.8 minutes on average, quantifying workflow impact.
09
A 2023 peer-reviewed evaluation reported that an AI model improved median time-to-diagnosis for radiology readouts by 24%, quantifying efficiency performance.
10
A 2021 peer-reviewed study on automated pathology image analysis reported a Cohen’s kappa of 0.81 between AI and expert pathologists, quantifying agreement on diagnostic interpretation.
Interpretation
Performance Metrics Interpretation
Across performance metrics, AI in life sciences is repeatedly showing measurable improvements, such as up to a 60% faster discovery of actionable drug combinations and pooled diabetic retinopathy screening performance of about 90% sensitivity and 93% specificity, indicating consistent efficiency and diagnostic accuracy gains.
06 · Category
Cost Analysis9 stats
01
$10.2 billion in annual cost savings potential in healthcare from AI-enabled automation was estimated for the U.S. (McKinsey), quantifying value opportunity
02
A 2019 study estimated that AI can reduce R&D costs for pharma by up to 30% across certain stages (peer-reviewed/industry syntheses), quantifying a potential cost envelope
03
A 2022 Cost/benefit modeling study reported that AI-enabled remote patient monitoring reduced hospital readmissions by 12% in the evaluated dataset (peer-reviewed), quantifying savings-linked outcomes
04
A 2020 peer-reviewed evaluation found that AI automated radiology worklist prioritization reduced turnaround time by 26% (measured), quantifying cost/time benefit
05
A 2022 study in JAMA Network Open estimated that remote monitoring programs could reduce total cost of care by 5% to 10% per patient-year in evaluated cohorts, quantifying cost impact mechanisms for AI-adjacent RPM.
06
A 2021 peer-reviewed evaluation of AI-assisted radiology workflow prioritization reported reduction in cost per case by 18% compared with baseline operations, quantifying operational cost savings.
07
A 2020 cost-effectiveness analysis reported that an AI-supported screening strategy for a defined population reduced downstream diagnostic costs by $12.3per person screened, quantifying savings in screening pathways.
08
A 2019 industry study estimated that AI-driven drug discovery and development can reduce the cost of bringing a new drug to market by 10% to 20% (scenario-based), quantifying a potential R&D cost envelope.
09
A 2022 health technology assessment reported incremental cost-effectiveness for an AI imaging triage tool at an incremental cost of $38,400per QALY gained, quantifying cost-effectiveness results for an AI tool.
Interpretation
Cost Analysis Interpretation
Across healthcare’s AI cost analyses, studies consistently point to sizable but measurable savings, from a 12% reduction in hospital readmissions and 5% to 10% lower total cost of care per patient-year to R&D cost cuts up to 30% for pharma, with additional cost-effectiveness evidence like $38,400 per QALY for an AI imaging triage tool.
07 · Category
Industry Trends1 stats
01
In the U.S., FDA’s Digital Health Center of Excellence reported that AI/ML-enabled medical devices are increasingly represented among its cleared/authorized software submissions, with AI-related submissions comprising 18% of digital health software submissions in 2023.
Interpretation
Industry Trends Interpretation
Under Industry Trends, the FDA’s Digital Health Center of Excellence shows that AI and ML are rapidly becoming a bigger part of the digital health pipeline, with AI related submissions making up 18% of software submissions in 2023 in the U.S.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). AI In The Life Sciences Industry Statistics. Gitnux. https://gitnux.org/ai-in-the-life-sciences-industry-statistics
MLA
Ryan Townsend. "AI In The Life Sciences Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ai-in-the-life-sciences-industry-statistics.
Chicago
Ryan Townsend. 2026. "AI In The Life Sciences Industry Statistics." Gitnux. https://gitnux.org/ai-in-the-life-sciences-industry-statistics.
Sources & references
40 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)